Comparative Study of Blood, Tissue and Serum Levels of Carcinoembryonic Antigen (CEA) Detection in Breast Cancer

Moazzezy, Neda; Bouzari, Saeid; Oloomi, Mana

doi:10.31557/apjcp.2019.20.10.2979

Cited by 5 publications

(5 citation statements)

References 27 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In normal breast, we demonstrated that in fact a minor subset of normal luminal breast epithelial cells do express CEACAM5, and that positive cells preferably are present as part of a mature luminal compartment. While it has not been reported previously by immunohistochemistry [17,22,23,29], presence of CEACAM5 in normal breast tissue has been detected with RT-PCR [36]. Previously, we have examined CEACAM6 and found a similar correlation to a differentiation hierarchy both in normal epithelial tissue and in breast cancer [31].…”

Section: Figure 3: Pairs Of Primary Breast Cancer and Lymph Node Metamentioning

confidence: 88%

Heterogeneity of CEACAM5 in breast cancer

et al. 2020

View full text Add to dashboard Cite

CEACAM5 is overexpressed in many primary breast carcinomas. However, the exact role of CEACAM5 in breast cancer tumorigenesis remains unresolved. Here, we examined a repository of 110 cryopreserved primary breast carcinomas by immunohistochemistry to assess the distribution of CEACAM5 in tumor subtypes. The majority of estrogen receptor-positive and HER2-overexpressing tumors were CEACAM5-positive, whereas most of Triple-negative tumors were negative. Assessing sample sets of paired primary breast cancers and corresponding lymph node lesions from a total of 59 patients revealed a high correlation between primary tumor and lymph node with regard to CEACAM5-status. However, a notable subset of sample sets demonstrated intratumoral heterogeneity in the primary tumor, the metastatic lesion or both, suggesting that both CEACAM5-positive and-negative cells can play a role in tumor dissemination. When examining the consequence of expression of CEACAM5 in breast cancer cell lines in culture assays we found that CEACAM5-expressing cells were less invasive. In survival analysis, using cohort studies of breast cancer, expression of CEACAM5 predicted different clinical outcomes depending on molecular subtypes. Altogether, our analysis suggests that CEACAM5 plays a context-dependent role in breast cancer that warrants further investigation.

show abstract

Section: Figure 3: Pairs Of Primary Breast Cancer and Lymph Node Metamentioning

confidence: 88%

Heterogeneity of CEACAM5 in breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Likewise, as far as we know, it is the first study that has assessed CEA as a target for a murine allograft model of BC. Indeed, the serum CEA level is a parameter widely used in the clinical diagnosis and prognosis of BC [37,38]. Therefore, there are many patents claiming to have developed kits or platforms based on CEA for BC diagnosis [39][40][41][42][43][44].…”

Section: Discussionmentioning

confidence: 99%

“…Besides its versatility and applicability for TNBC, MFCEA might benefit patients with different neoplasias. The anti-CEA decoration of nanoparticles may make MFCEA able to target any CEA positive malignant tumor such as breast, colorectal, ovarian, bladder, bronchial, lung, stomach and pancreatic cancers [14,37,[73][74][75][76][77][78][79][80][81], making it a promising theranostic nanodevice for management of various types of cancer and metastasis. In conclusion, the biocompatibility of MFCEA and its ability to target and to remain in CEA positive tumors make this nanomaterial a promising device for cancer management; however, further studies must be carried out to improve its performance and ensure its safety.…”

Section: Discussionmentioning

confidence: 99%

Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer

et al. 2021

View full text Add to dashboard Cite

Systemic therapy is generally required for breast cancer. However, treatment toxicity and side effects are a concern, especially for triple-negative breast cancer (TNBC), a subtype that usually develops resistance to chemotherapy. To overcome this issue, new nanoformulations capable of targeting cancer cells have been developed and alternative biomarkers have been explored as target molecules for TNBC management. In this study, we performed an in vivo assay in a murine orthotopic TNBC model to evaluate the targeting ability of anti-carcinoembryonic antigen (anti-CEA) loaded nanoparticles (labelled MFCEA), which had been previously synthetized by our research group. 4T1 cells were injected in the mammary gland of balb-c mice, and tumors were evaluated for CEA expression by immunohistochemistry. Tumor-bearing mice received targeted (MFCEA) and non-targeted (MF) nanoparticles intraperitoneally. Tumors were removed 1, 4, 15 and 24 h after treatment, and Prussian blue iron staining was performed. Our results showed, as far as we know for the first time, that 4T1 induced tumors are CEA positive, and this opens up new prospects for treating TNBC. Furthermore, MFCEA nanoparticles were able to target malignant tissue and were retained in the tumor for longer than MF nanoparticles. The retention property of MFCEA, together with the absence of toxicity observed in the MTT assay, make these nanoparticles a promising device for management of CEA positive tumors and perhaps for TNBC. Nevertheless, further studies must be carried out to improve their performance and ensure safety for clinical studies.

show abstract

“… 10 It has clinical application in monitoring the condition of lung cancer and judging the curative effect and prognosis. 11 CYFRA21-1 is highly expressed in various types of tumor epithelial cells, and gradually released into the blood circulation with tumor cell apoptosis. 12 In recent years, research projects have found that the concentration of TuM2-PK in the peripheral blood of tumor patients has significantly increased, which can be used for early diagnosis, prognosis assessment, and therapeutic monitoring of tumors.…”

Section: Introductionmentioning

confidence: 99%

The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer

Li,

Xu,

Wang

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objective: Finding biomarkers related to non-small cell lung cancer (NSCLC) is helpful for the diagnosis and precise treatment of lung cancer. The relationship between serum tumor M2-pyruvate kinase (TuM2-PK), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment (CYFRA21-1) and NSCLC was analyzed. Methods: The serum levels of TuM2-PK, CEA, and CYFRA21-1 in 184 patients with the NSCLC group, 60 patients with the benign lung disease (BLD) group, and 90 healthy controls (HC) group were detected. The levels of TuM2-PK were measured by using an enzyme-linked immunosorbent assay. The detection methods of CEA and CYFRA21-1 were electrochemiluminescence. The receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of TuM2-PK, CEA, and CYFRA21-1 on NSCLC. The Kaplan–Meier survival curve was drawn to evaluate the survival status in NSCLC patients with different serum levels of TuM2-PK, CEA, and CYFRA21-1. Results: Serum levels of TuM2-PK, CEA, and CYFRA21-1 in the NSCLC group were significantly higher than those in the BLD group and the HC group ( P < .01). Serum levels of TuM2-PK, CEA, and CYFRA21-1 in NSCLC patients were associated with the tumor lymph node metastasis stage ( P < .05), lymph node metastasis ( P < .05), and distant metastasis ( P < .05). The ROC curve showed that the area under the curve of serum levels of TuM2-PK, CEA, and CYFRA21-1 was 0.814, 0.638, and 0.719, respectively, and that the combination of the above 3 was 0.918. The Kaplan–Meier survival curve showed that the 1-, 3- and 5-year survival rate in NSCLC patients with positive TuM2-PK, CEA, and CYFRA21-1 was significantly lower than that in NSCLC patients with negative TuM2-PK, CEA, and CYFRA21-1, respectively ( P < .05). Conclusions: Serum TuM2-PK, CEA, and CYFRA21-1 levels have high clinical values in the diagnosis of NSCLC, and can effectively judge the prognosis of patients.

show abstract

Comparative Study of Blood, Tissue and Serum Levels of Carcinoembryonic Antigen (CEA) Detection in Breast Cancer

Abstract: surgery (Wang et al., 2010). Reverse transcription polymerase chain reaction (RT-PCR) as a molecular technique has been used to measure tumor-specific mRNA expression. Tumor-specific mRNAs are specifically expressed and they will be markedly up regulated in tumor

Cited by 5 publications

References 27 publications

Heterogeneity of CEACAM5 in breast cancer

Heterogeneity of CEACAM5 in breast cancer

Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer

The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About